Table 2.
The relationship between CD44v6 and integrin-β1 mRNA expression and clinical pathological features of patients with PC
| Pathological features | N |
CD44v6 mRNA expression |
P value |
Integrin-β1 mRNA expression |
P value |
||
|---|---|---|---|---|---|---|---|
| High | Low | High | Low | ||||
| Sex |
|
|
|
0.238 |
|
|
0.132 |
| Male |
27 |
12 (54.5%) |
15 (45.5%) |
|
13 (48.1%) |
14 (51.9%) |
|
| Female |
27 |
10 (37.0%) |
17 (63.0%) |
|
8 (29.6%) |
19 (70.4%) |
|
| Age |
|
|
|
0.921 |
|
|
0.810 |
| ≤60 |
24 |
10 (41.7%) |
14 (58.3%) |
|
9 (37.5%) |
15 (62.5%) |
|
| >60 |
30 |
12 (40.0%) |
18 (60.0%) |
|
12 (40.0%) |
18 (60.0%) |
|
| Tumor location |
|
|
|
0.235 |
|
|
0.241 |
| Head and Body PC |
34 |
12 (35.3%) |
22 (64.7%) |
|
14 (41.2%) |
20 (58.8%) |
|
| Tail PC |
20 |
10 (50.0%) |
10 (50.0%) |
|
7 (35.0%) |
13 (65.0%) |
|
| Clinical stages |
|
|
|
0.016 |
|
|
0.023 |
| I+II |
21 |
4 (19.0%) |
17 (81.0%) |
|
4 (18.2%) |
18 (81.8%) |
|
| III+IV |
33 |
18 (54.5%) |
15 (45.5%) |
|
17 (53.1%) |
15 (46.9%) |
|
| Tumor differentiation |
|
|
|
<0.01 |
|
|
0.067 |
| Poorly and Moderately |
33 |
7 (21.2%) |
26 (78.8%) |
|
9 (29.0%) |
22 (71.0%) |
|
| Highly |
21 |
15 (71.4%) |
6 (28.6%) |
|
12 (52.2%) |
11 (47.8%) |
|
| Tumor size (diameter) |
|
|
|
0.187 |
|
|
0.114 |
| ≤4 cm |
25 |
8 (32.0%) |
17 (68.0%) |
|
7 (28.0%) |
18 (72.0%) |
|
| >4 cm |
29 |
14 (48.3%) |
15 (51.7%) |
|
14 (48.3%) |
15 (51.7%) |
|
| LNM |
|
|
|
0.028 |
|
|
0.034 |
| Negative |
20 |
4 (20.0%) |
16 (80.0%) |
|
6 (23.1%) |
20 (76.9%) |
|
| Positive |
34 |
18 (52.9%) |
16 (47.1%) |
|
15 (53.6%) |
13 (46.4%) |
|
| Liver metastasis |
|
|
|
0.020 |
|
|
0.028 |
| Negative |
24 |
5 (20.8%) |
19 (79.2%) |
|
5 (20.8%) |
19 (79.2%) |
|
| Positive |
30 |
17 (56.7%) |
13 (43.3%) |
|
16 (53.3%) |
14 (46.7%) |
|
| CA199(U/ml) |
|
|
|
0.887 |
|
|
0.165 |
| ≤1000 |
18 |
7 (38.9%) |
11 (61.1%) |
|
5 (27.8%) |
13 (72.2%) |
|
| >1000 |
36 |
15 (41.7%) |
21 (58.3%) |
|
16 (44.4%) |
20 (55.6%) |
|
| KPS |
|
|
|
0.665 |
|
|
0.841 |
| ≤80 |
25 |
11 (44.0%) |
14 (56.0%) |
|
10 (40.0%) |
15 (60.0%) |
|
| >80 | 29 | 11 (37.9%) | 18 (62.1%) | 11 (37.9%) | 18 (62.1%) | ||